| Ex-Date | Pay Date | Amount | Change |
|---|---|---|---|
| NT$1.00 | -16.67% | ||
| NT$1.00 | -16.67% | ||
| NT$1.20 | 20% | ||
| NT$1.20 | 20% | ||
| NT$1.00 | 0% | ||
| NT$1.00 | 0% | ||
| NT$1.00 | 66.67% | ||
| NT$0.60 | |||
Chi Sheng Pharma & Biotech Co Ltd pays a dividend yield (FWD) of 3.84%.
- ISIN
- WKN
- -
- Symbol / Exchange
- / ROCO
- Value
- €0.74
- Dividend frequency
- annually
- Security Type
- Equity
- Sector
Health Care
- Country
Taiwan
- Dividend Currency
- New Taiwan Dollar
- Within the last 12 months, Chi Sheng Pharma & Biotech Co Ltd paid a dividend of NT$1.20. For the next 12 months, Chi Sheng Pharma & Biotech Co Ltd is expected to pay a dividend of NT$1.00. This corresponds to a dividend yield of approximately 3.84%.
- The dividend yield of Chi Sheng Pharma & Biotech Co Ltd is currently 3.84%.
- Chi Sheng Pharma & Biotech Co Ltd pays annually dividends. Payout is in September.
- The next dividend will be paid on 20 September 2024.
- Within the last 10 years, Chi Sheng Pharma & Biotech Co Ltd has paid dividends in 5 of them.
- Dividends of NT$1.00 are expected for the next 12 months. This corresponds to a dividend yield of 3.84%.
- Chi Sheng Pharma & Biotech Co Ltd is assigned to the sector "Health Care".
- The last stock split of Chi Sheng Pharma & Biotech Co Ltd was on 17 September 2015 in the ratio 1040:1000.
- In order to receive the future dividend from Chi Sheng Pharma & Biotech Co Ltd on 20 September 2024 you must have purchased your Chi Sheng Pharma & Biotech Co Ltd shares before the ex-date on 23 August 2024.
- To receive the last dividend of Chi Sheng Pharma & Biotech Co Ltd on 22 September 2023 in the amount of NT$1.20 you had to have the stock in your portfolio before the ex-day on 22 August 2023.
- The last dividend was paid on 22 September 2023.
- In 2022, dividends of NT$1.00 were paid by Chi Sheng Pharma & Biotech Co Ltd.
- Dividends from Chi Sheng Pharma & Biotech Co Ltd are paid in New Taiwan Dollar.
- The headquarters of Chi Sheng Pharma & Biotech Co Ltd is located in Taiwan.